

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :
KAESEMEYER : Confirmation No. 6530
Serial No. 10/763,309 : Group Art Unit: 1623
Filed: January 23, 2004 : Examiner: Lawrence E. Crane

For: PHARMACEUTICAL COMPOSITION COMPRISING CITRULLINE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.

Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, appearing to read 'Raymond A. Miller', with a long horizontal flourish extending to the right.

Raymond A. Miller
Registration No. 42,891

Pepper Hamilton LLP
500 Grant Street, 50th Floor
Pittsburgh, PA 15219
Telephone: (412) 454-5000
Facsimile: (412) 281-0717
Date: June 21, 2007

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known					
				Application Number	10/763,309				
				Filing Date	January 23, 2004				
				First Named Inventor	Kaesemeyer				
				Group Art Unit	1623				
Examiner Name				Lawrence E. Crane					
Sheet	1	of	1	Attorney Docket Number		126625.00801			
U.S. PATENT DOCUMENTS									
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		Number	Kind Code (if known)						
FOREIGN PATENT DOCUMENTS									
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
		Office	Number	Kind Code (if known)					
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.							T
	C1	GENNARO ed., Remington's Pharmaceutical Sciences 18 th ed., 1990, Mack Publishing Co., Easton, PA (Table of Contents)							
	C2	BOYLAN et al. eds., Handbook of Pharmaceutical Excipients, 1986, Publ. by American Pharmaceutical Assoc., Washington, DC (Table of Contents)							
	C3	LIEBERMAN et al. eds., Pharmaceutical Dosage Forms, Tablets, 1990, Marcel Dekker, Inc., New York, NY (Table of Contents)							
	C4	DRAPER et al., Contrasting Effect of Nitric Oxide Synthase Inhibition on LV Function During Early and Late Reoxygenation, International Society for Heart Research European Section XVIII European Section Meeting, Versailles, France, July 2-5, 1997, Journal of Molecular and Cellular Cardiology, pg. A97(Fr99)							
Examiner Signature					Date Considered				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.